Marc Feldmann is a professor at the Kennedy Institute of Rheumatology at the University of Oxford. He trained in medicine at Melbourne University and then earned a Ph.D. in Immunology at the Walter & Eliza Hall Institute with Sir Gus Nossal. Feldmann’s research interests are mechanisms of autoimmunity and the role of cytokines in disease.
Together with Sir Ravinder Maini, Feldmann made a major discovery by uncovering the importance of TNF in rheumatoid arthritis and consequently developing anti-TNF therapy. This has led to his election to the Royal Society, the National Academy of Sciences, and the Australian Academy of Science, and to major prizes: Crafoord Prize of the Royal Swedish Academy of Sciences Award, the Albert Lasker Clinical Research Award, and the Canada Gairdner Award.
Feldmann’s current interests are to define new treatments for unmet needs, using a cytokine approach and more cost-effective therapy of RA, and getting closer to a cure.
